GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited evidence and unknown long-term risks.
Catch up on global daily news
Compelling long reads
Future-gazing analysis, predictions and speculation
Tune into captivating conversations
Watch engaging short films
A handpicked article read aloud from the latest issue of The Economist
The expiry of patents in China, India and elsewhere will boost uptake dramatically
New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective and…
Animal studies suggest rapamycin is as effective as long-term fasting
Researchers point to a grocers’ favourite
Research suggests multivitamin supplements may offer some cognitive benefits for older adults and slow biological ageing markers,…
